Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3996586 | 0.92 | — | — | |
| SCHEMBL11555092 | 0.84 | — | — | |
| Dimethylamine SCHEMBL5605144 | 0.84 | CYP1A2 (0.34) | TSHRCYP1A2CYP2C19 | |
| Dimethylamine SCHEMBL5604576 | 0.82 | TSHR (0.39) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL7469737 | 0.81 | — | — | |
| SCHEMBL8608090 | 0.79 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| Propylamine SCHEMBL18588043 | 0.78 | DNM1 (0.35) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL422834 | 0.78 | — | — | |
| SCHEMBL2531078 | 0.77 | DNM1 (0.60) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL18852183 | 0.77 | DNM1 (0.33) | DNM1MEN1KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499577-B1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-6946471-B2 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1499577-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-26 | — | — | EP | disclosed |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | BRANDT MICHAEL | 2004-10-28 | — | — | US | disclosed |
| US-6790852-B2 | HETEROCYCLIC NITROGEN COMPOUNDS SUCH AS 2-(2,6-DICHLOROPHENYL) -4-(3-BROMOPHENYL)-5-(2-(3- HYDROXYPROPYLAMINO)PYRIMIDIN-4-YL) -N-H-IMIDAZOLE, USED AS TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC OR ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2004-09-14 | — | — | US | disclosed |
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | US | disclosed |
| WO-2003087026-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | CYP2D6, CYP2F1, CYP1A2 | DNM1 659/4885MEN1 1726/4885KMT2A 933/4885 |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | CYP2D6, CYP1A2, CYP2F1 | DNM1 690/4885MEN1 1918/4885KMT2A 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.